Top Page
KP Tissue
(TSX:KPT)
KP Tissue (KPT) vs. iShares MSCI Canada ETF (EWC)
KP Tissue Business Overview & Revenue Model
KP Tissue Earnings Call Summary
KP Tissue Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 76.09M | 264.78M | 238.61M | 115.99M | 153.43M | 197.84M |
| Net Income | 4.43M | 2.43M | -4.94M | -10.25M | 1.24M | -1.95M |
Balance Sheet | ||||||
| Total Assets | 70.52M | 71.31M | 70.61M | 81.71M | 80.72M | 71.31M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.80M | 1.80M | 2.25M | 7.68M | 4.85M | 4.99M |
| Stockholders Equity | 68.72M | 69.52M | 68.36M | 74.03M | 75.87M | 66.33M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | 6.98M | 6.62M | 1.15M | -2.44M |
| Operating Cash Flow | 0.00 | 0.00 | 6.98M | 6.62M | 1.15M | -2.44M |
| Investing Cash Flow | 6.97M | 6.97M | 6.98M | 6.62M | 5.56M | 5.59M |
| Financing Cash Flow | -5.23M | -6.97M | -6.98M | -6.62M | -5.56M | -5.59M |
KP Tissue Technical Analysis
KP Tissue Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | C$410.78M | 14.33 | 15.23% | 6.57% | 8.87% | 10.15% | |
73 Outperform | C$410.78M | 14.54 | 15.23% | 6.34% | 8.87% | 10.15% | |
70 Outperform | C$245.80M | 11.06 | 8.25% | 4.71% | -2.11% | ― | |
68 Neutral | C$784.47M | 12.16 | 14.63% | 5.99% | 6.57% | 8.61% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | C$102.16M | 26.24 | 5.55% | 7.04% | ― | -39.19% | |
58 Neutral | C$427.49M | 9.25 | 8.60% | 4.83% | 6.15% | -36.76% |
KP Tissue Corporate Events
KP Tissue Inc. announced that Kruger Products Inc. has successfully closed a CDN $165 million offering of senior unsecured notes due in 2032. The proceeds from this offering will be used to repay existing borrowings and for general corporate purposes. Additionally, KPI’s syndicated credit agreement has been amended to increase its facility amount and add Kruger Products SB Inc. as a restricted credit party, which could enhance the company’s financial flexibility and operational capacity.
The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.
KP Tissue Inc. announced that Kruger Products Inc. will issue and sell CDN $165 million in Senior Unsecured Notes due in 2032 through a private placement, with the offering expected to close on December 10, 2025. The proceeds from this offering will be used to repay borrowings under Kruger Products SB Inc.’s senior credit facilities and for general corporate purposes, potentially strengthening KPI’s financial position and operational flexibility.
The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.
KP Tissue Inc. announced that Kruger Products Inc. plans to offer CAD $165 million in Senior Unsecured Notes through a private placement. The proceeds will be used to repay borrowings under Kruger Products SB Inc.’s senior credit facilities and for general corporate purposes, which is expected to improve the credit profile of the restricted group. The Notes will not be registered under U.S. or Canadian securities laws, and the offering is subject to market conditions.
The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.
KP Tissue Inc. reported a 7.7% increase in revenue for Q3 2025, reaching $561.1 million, driven by higher sales volumes and favorable pricing. The company also announced plans to build a new TAD tissue facility by 2028 to support its growth in ultra-premium products, reflecting its strategic focus on expanding market share and enhancing operational capacity.
The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.
KP Tissue Inc. reported a 7.7% increase in revenue to $561.1 million for Q3 2025, with Adjusted EBITDA rising by 30.4% to $85.7 million, driven by higher sales volumes and favorable pricing. Despite a decrease in net income due to foreign exchange losses and increased tax expenses, the company is focusing on long-term growth by announcing the construction of a new TAD tissue facility set to begin operations in 2028, aiming to meet the rising demand for ultra-premium products.
The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.
KP Tissue Inc. announced a quarterly dividend of $0.18 per common share, payable on January 15, 2026, to shareholders of record as of December 31, 2025. This dividend declaration is linked to a corresponding distribution by Kruger Products Inc., in which KPT holds a 12.1% interest. Additionally, KPT offers a Dividend Reinvestment Plan (DRIP) for Canadian shareholders, allowing them to reinvest cash dividends into additional common shares, subject to specific conditions and eligibility requirements.
The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.